vendredi 9 novembre 2018

Onco Actu du 9 novembre 2018

1. Biologie

Study identifies cause of fragile envelopes in many cancer cells [Dana-Farber Cancer Institute]

3.1.1 Prévention - Tabac - e-cigs

F.D.A. Plans to Ban Most Flavored E-Cigarette Sales in Stores [NY Times]

U.S. to restrict e-cigarette flavors to fight teenage vaping 'epidemic' [Reuters]

4. Dépistage, diagnostic et pronostic

Doctor and dad duo design new 'cancer maps' to aid diagnosis [Cancer Research UK]

4.7 Dép., diag. & prono. - Col de l'utérus

Mailed HPV tests can help find women at-risk for cervical cancer, study finds [UNC Lineberger]

5. Traitements

Oncology in Transition - Changes, Challenges, and Opportunities [JAMA]

5.10 Traitements - Essais

Drugmakers seek clarity on guidance on use of placebo and blinding in oncology trials [EndPoints]

5.12.3 Immunothérapies-combinaisons

Combination chemotherapy and immunotherapy effective in Phase II leukemia study [MD Anderson Cancer Center]

5.12.7 Immunothérapies - vaccins

Vaccines as an Integral Component of Cancer Immunotherapy [JAMA]

5.12.9 Immunothérapies - SITC

New Data from Investigational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting [Merck]

5.2.3 Pharma - économie

AstraZeneca chief says Europe should pay more for drugs—and the U.S. should pay less [FiercePharma]

AstraZeneca chief Pascal Soriot heralds the start of a ‘period of sustained growth for years to come’ [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to strengthen FDA’s expanded access program [FDA]

EMA’s Regulatory Science Strategy to 2025 [ESMO]

5.4 Traitements - Economie

ICR responds to NICE decision on olaparib for women with advanced ovarian cancer [Institute of Cancer Research]

National Institute for Health and Care Excellence (NICE) Recommends Jazz Pharmaceuticals' Vyxeos® (Daunorubicin and Cytarabine) for Adults with Specific Types of Secondary Acute Myeloid Leukaemia (AML) [Jazz Pharmaceuticals]

NICE nod for Jazz’ AML chemo [PharmaTimes]

Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer [NICE]

NICE fail to recommend AstraZeneca's cancer drug Olaparib on cost effectiveness basis [Pharmafile]

6.1 Observation

Eight Factors May Link Disparities in Cancer Death Rates and Income [NCI]

NHS cancer treatment wait statistics 'set to be worst on record' [The Guardian]

6.10 Politiques

Europe’s researchers benefit from reduced bureaucracy [Nature]

6.12 Ethique

Judge dismisses most of Carlo Croce’s libel case against the New York Times [Retraction Watch]

Sanger whistle-blowers dispute findings that cleared management of bullying [Nature]

6.5 Médecines alternatives/complémentaires

The Fred Hutchinson Cancer Center shows us how to write a press release on integrative oncology [Respectful Insolence]

6.6 Publications

Scientists struggle with confusing journal guidelines [Nature]

6.7 DMP, Big Data & applis

Google has hired Geisinger's David Feinberg to lead its health strategy [CNBC]

6.7.1 IA/bioinformatique

AI is not “magic dust” for your company, says Google’s Cloud AI boss [MIT Technology Review]

6.8 Communication

How minimally invasive surgery was spun as the ‘latest and greatest’ for cervical cancer [HealthNewsReview]